4528 — ONO PHARMACEUTICAL Share News
0.000.00%
Last trade - 00:00Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours
Table: Ono Pharm -Q1 group results (IFRS)
Table: Ono Pharm -2025/26 group results (IFRS)
Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say
Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Notice Concerning Disposal Of Treasury Shares By Third-Party Allotment
Brief: Congruence And Ono Pharma Expand Multi-Target Research Partnership
Promotion For Sglt2 Inhibitor Forxiga 5 Mg 10 Mg In Japan
Table: Ono Pharm -9-MTH group results (IFRS)
Table: Ono Pharm 6-MTH group results (IFRS)
Brief: Ono Announces Encouraging Efficacy Signals Of ONO-2808, A S1P5 Receptor Agonist, In An Interim Analysis Of Ongoing Phase 2 Clinical Trial In Patients With Multiple System Atrophy
Brief: Deciphera Receives European Commission Approval Of Romvimza (Vimseltinib)
Notice Concerning Establishment Of Ono Global Reinsurance, Inc. As An Overseas Subsidiary (Specified Subsidiary)
Table: Ono Pharm -Q1 group results (IFRS)
Brief: Deciphera Gets CHMP Nod for Romvimza (Vimseltinib) to Treat Tenosynovial Giant Cell Tumor
Brief: Vertex And Ono Pharmaceutical Announce Strategic Agreement To Develop & Commercialize Povetacicept In Japan & South Korea